Spots Global Cancer Trial Database for Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas

Official Title: Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas

Study ID: NCT00516607

Conditions

Brain and Central Nervous System Tumors

Interventions

enzastaurin hydrochloride

temozolomide

pharmacological study

Study Description

Brief Summary: RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving enzastaurin together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin when given together with temozolomide in treating patients with primary gliomas.

Detailed Description: OBJECTIVES: * To assess if full doses of enzastaurin hydrochloride and temozolomide can be used in combination for the treatment of patients with primary gliomas. * To determine the recommended phase II dose. OUTLINE: This is a multicenter study. Patients receive oral enzastaurin hydrochloride once or twice daily on days 1-28\* and oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: \*During the first course only, patients also receive enzastaurin hydrochloride on day -1. Patients undergo blood sample collection on day 22 of course 1 and on day 5 of course 2 for pharmacokinetic studies of enzastaurin hydrochloride. After completion of study treatment, patients are followed within 30 days and then every 3 months thereafter.